title: Development of olmesartan medoxomil lipid-based nanoparticles and nanosuspension: preparation, characterization and comparative pharmacokinetic evaluation.
abstract: The aim was to enhance the oral bioavailability of olmesartan medoxomil (OM) by preparing solid lipid nanoparticles (SLNs) and comparing with nanosuspension (OM-NS). OM-SLNs and OM-NS were prepared by known methods. Prepared SLNs were evaluated for physical characters and in vivo pharmacokinetic (PK) performance in rats. OM-NS showed more than four-fold increase in the solubility. During DSC and XRD studies, drug incorporated in SLNs was found to be in amorphous form. The relative bioavailability of OM-SLN and OM-NS was 7.21- and 3.52-fold when compared with that of coarse suspension. Further, OM-SLNs also increased the oral bioavailability by two-fold over that of OM-NS.
authors.affiliation: a Laboratory of Nanotechnology, Department of Pharmaceutical Sciences , University college of Pharmaceutical Sciences, Kakatiya University , Warangal , Telangana , India.
authors.forename: Arun
authors.initials: A
authors.lastname: B
authors.affiliation: a Laboratory of Nanotechnology, Department of Pharmaceutical Sciences , University college of Pharmaceutical Sciences, Kakatiya University , Warangal , Telangana , India.
authors.forename: Narendar
authors.initials: N
authors.lastname: D
authors.affiliation: a Laboratory of Nanotechnology, Department of Pharmaceutical Sciences , University college of Pharmaceutical Sciences, Kakatiya University , Warangal , Telangana , India.
authors.forename: Kishan
authors.initials: K
authors.lastname: Veerabrahma
mesh_terms: D000818:Animals; D001682:Biological Availability; D004337:Drug Carriers / Q000737:chemistry* / Q000493:pharmacokinetics*; D008055:Lipids / Q000737:chemistry* / Q000493:pharmacokinetics*; D008297:Male; D053758:Nanoparticles / Q000737:chemistry*; D000068557:Olmesartan Medoxomil / Q000737:chemistry*; D010316:Particle Size; D051381:Rats; D017208:Rats, Wistar; D012995:Solubility; D013535:Suspensions
chemical_list: D004337:Drug Carriers; D008055:Lipids; D013535:Suspensions; D000068557:Olmesartan Medoxomil
keywords: Olmesartan medoxomil; bioavailability; nanosuspension; pharmacokinetics; solid lipid nanoparticles